Yabe D, Shiki K, Homma G, Meinicke T, et al. Efficacy and safety of the sodium-glucose co-transporter-2 inhibitor empagliflozin in elderly Japanese adults (>/=65 years) with type 2 diabetes: A randomized, double-blind, placebo-controlled, 52-week clinical trial (EMPA-ELDERLY). Diabetes Obes Metab 2023 Aug 25. doi: 10.1111/dom.15249.
PMID: 37622398